1 Division of Nephrology and Hypertension, Georgetown University Medical Center, Washington, District of Columbia 20007; and 2 Second Department of Internal Medicine, University of Tokyo, Tokyo, Japan
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The spontaneously
hypertensive rat (SHR) has enhanced tubuloglomerular feedback (TGF)
responses and diminished buffering by juxtaglomerular apparatus
(JGA)-derived nitric oxide (NO) despite enhanced expression of NO
synthase (NOS) isoforms in the JGA. We tested the hypothesis that the
enhanced TGF response is due to inactivation of NO by oxygen radicals
(O2). SHR had significantly (P < 0.05) greater expression of the peroxynitrate reaction product,
nitrotyrosine, in renal cortex. A membrane-permeant, metal-independent superoxide dismutase mimetic, tempol, was used to
test the functional role of O
2.
Maximum TGF responses, assessed from changes in proximal stop-flow
pressure (PSF) during orthograde loop of Henle (LH)
perfusion of artificial tubular fluid (ATF), were enhanced in SHR
[Wistar-Kyoto rat (WKY) 8.8 ± 0.4 (n = 30 nephrons) vs.
SHR 10.8 ± 0.4 mmHg (n = 39 nephrons), P < 0.001]. TGF responses of SHR were unresponsive to microperfusion of 7-nitroindazole (7-NI, 10
4 M), which
is an inhibitor of neuronal NOS (nNOS) [WKY 8.3 ± 0.3 to 10.8 ± 0.4 (n = 8, P < 0.001) vs. SHR 10.0 ± 0.7 to 10.5 ± 0.8 mmHg (n = 8; not significant)].
Microperfusion of tempol (10
4 M) into
the efferent arteriole (EA) supplying the peritubular capillaries (PTC)
blunted TGF. The response to tempol was significantly (P < 0.05) greater in SHR [
TGF in WKY 19 ± 6% (n = 10)
vs. SHR 32 ± 3% (n = 10)]. Microperfusion of the NO
donor compound
S-nitroso-N-acetyl-penicillamine (SNAP,
10
7-10
4
M) via the LH blunted TGF, but the sensitivity of the response was
impaired significantly (P < 0.05) in SHR nephrons. PTC
perfusion of tempol (10
4 M) normalized
the response to loop perfusion of both SNAP and 7-NI in SHR nephron to
levels in WKY (during tempol,
PSF with 7-NI in WKY 8.9 ± 0.6 to 11.4 ± 0.8; n = 12 vs. SHR 9.5 ± 0.5 to 12.5 ± 0.4 mmHg; n = 16). In conclusion, TGF responses are enhanced in SHR, in part due to a diminished role for NO from nNOS in
blunting TGF due to enhanced O
2
formation. O
2 in the JGA enhances TGF
responses by inactivation of locally generated NO.
7-nitroindazole; superoxide dismutase; tempol; S-nitroso-N-acetyl-penicillamine; nitrotyrosine; nitric oxide synthase
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
NITRIC OXIDE (NO) is implicated in the regulation of renal vascular resistance, glomerular filtration, tubular reabsorption, renin secretion, and tubuloglomerular feedback (TGF) responses (15, 36-38). TGF is a vasoconstrictive response of the afferent arteriole that reduces the glomerular capillary pressure and the single-nephron glomerular filtration rate (SNGFR) during reabsorption of NaCl by the macula densa segment (7). This vasoconstrictive response is enhanced in the spontaneously hypertensive rat (SHR) model of hypertension and may contribute to renal mechanisms for the development of hypertension (9). A neuronal or type I isoform of nitric oxide synthase (nNOS) is heavily expressed in macula densa cells (35, 39) and an endothelial or type III isoform of NOS (eNOS) is expressed in microvascular and glomerular capillary endothelium (33, 35). Pharmacological studies have shown that nNOS in macula densa cells is activated during NaCl reabsorption. The ensuing generation of NO offsets the primary vasoconstrictive effects of TGF on the afferent arteriole and diminishes further NaCl reabsorption by the macula densa cells (39). The overactive TGF in the genetic SHR model of hypertension has been ascribed to a diminished role for macula densa NO in buffering the vasoconstrictive response (34, 36). Thus SHR has a diminished or absent TGF response to local inhibition of NOS in the juxtaglomerular apparatus (JGA) with nitro-L-arginine (NLA) (34) or nNOS with 7-nitroindazole (7-NI) (36).
The cause for the diminished blunting of TGF by NO in nephrons of SHR is presently unexplained. The mRNA and protein expression for nNOS and eNOS in the JGA of SHR is enhanced compared with control Wistar-Kyoto rats (WKY) (36). TGF is unresponsive to microperfusion of the NOS substrate L-arginine or the NOS cofactor tetrahydrobiopterin or its precursor sepiapterin into the macula densa segment (36). Therefore, there does not appear to be a defect in the expression of constitutive NOS isoforms, or in the delivery of NOS substrate or cofactors to the JGA to explain the defective function of NO in the SHR.
The aorta of SHR has an impaired endothelium-derived relaxing factor
(EDRF) response. This is ascribed to an endothelium-derived contraction
factor (EDCF) that can inactivate NO (18). The precise identity of EDCF
remains unclear, but its generation or action depends on oxygen
radicals (O2).
O
2 interacts with NO to yield
peroxynitrate (ONOO
), which effectively reduces the
biological half-life of NO. Peroxynitrate itself can interact with
tyrosine residues to form nitrotyrosine. In the 2-kidney, 1-clipped rat
model of hypertension, nitrotyrosine immunoreactive expression is
prominent in the extraglomerular mesangium and interstitium between the
macula densa cells and the afferent arteriole (5). Therefore, the JGA
appears to be a prominent site for generation of
O
2 that could inactivate NO formed in
the macula densa.
We tested the hypothesis that a defect in NO function in the JGA of the
SHR despite ongoing NO generation could be ascribed to enhanced
degradation of NO via interaction with
O2. Nitrotyrosine immunoreactivity was
used to assess the net interaction between renal NO and
O
2. TGF responses to microperfusion of
7-NI were used to assess the role of nNOS in the macula densa. The
response to NO was assessed by microperfusion of
S-nitroso-N-acetyl-penicillamine (SNAP), which is an NO
donor compound. The nitroxide, tempol
(2,2,6,6-tetramethyl-1-piperidinyloxy, 8-hydroxy form), is
a low-molecular-weight membrane-permeant, metal-independent, stable, superoxide dismutase (SOD) mimetic that is
used as an O
2 spin trap. Tempol was microperfused into the vasculature surrounding the JGA to assess the
role of O
2.
![]() |
METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Studies were undertaken on male SHR and WKY weighing 241 ± 11 g and maintained on a standard rat chow (Purina, St. Louis, MO) with a sodium content of 0.3 g/100 g. They were allowed free access to food and water until the day of study.
Series 1: Western analysis of nitrotyrosine abundance in renal
cortex. These studies were designed to test the hypothesis that
there is enhanced nitrotyrosine immunoreactivity in the kidney of the
SHR. Under pentobarbital anesthesia (100 mg/kg ip), the abdomen was
opened, and the aorta was cannulated to allow flushing of the kidneys
with ice-cold buffered saline at pH 7.4. The kidneys were removed and
stored at 80°C until analyzed. The cortex was homogenized in
a glass tissue homogenizer (Iwaki, Chiba, Japan) in 1 ml buffer
containing 20 mM Tris, pH 7.2, 0.5 mM EGTA, 1 mM leupeptin, 1 mM DTT,
and 0.1 mM phenylmethylsulfonyl fluoride. Homogenates were sonicated
three times for 40 s and centrifuged at 12,000 g for 15 min.
The supernatants were diluted in an equivalent volume of SDS buffer
[0.5 M Tris-HCl pH 6.8, 20% (vol/vol) glycerol, 4.6% (wt/vol)
SDS] and boiled for 5 min. Protein amount in the renal cortex
homogenate was measured by the Bradford method (Bio-Rad, Richmond, CA).
Samples containing 150 µg protein were applied to an 8% SDS gel, and
proteins were separated by SDS-PAGE and electroblotted to a
nitrocellulose membrane (Pierce, Rockford, IL). The membrane was
stained by Ponceau solution to verify the protein transfer to the
membrane was complete. The nitrocellulose membranes were incubated with
5% nonfat dry milk in Tris-buffered saline with 0.1% Tween 20 (TBST) for 1 h, followed by overnight incubation with a
monoclonal antibody for nitrotyrosine (Upstate Technology, Lake Placid, NY) in a 1:200 dilution. After
rinsing in TBST, membranes were incubated for 2 h with an horseradish peroxidase (HRP)-conjugated secondary antibody against mouse IgG at a
1:1,000 dilution. HRP labeling was detected by diaminobenzidine with
0.3% H2O2.
Series 2: Maximal TGF responses to luminal microperfusion of the
nNOS inhibitor, 7-NI, and effects of efferent arteriolar microperfusion
of tempol. These experiments were designed to test the hypothesis
that the enhanced TGF responses of SHR nephrons could be ascribed to a
blunted generation of NO by nNOS in the macula densa because of
enhanced degradation by O2. Groups of
SHR and age-matched WKY rats were prepared for in vivo micropuncture, microperfusion, and TGF studies as described in detail previously. In brief, animals weighing 210-275 g were
anesthetized with thiobarbital (Inactin, 100 mg/kg ip; Research
Biochemicals International, Natick, MA). A catheter was placed in a
jugular vein for fluid infusion and in a femoral artery for recording of mean arterial pressure (MAP) from the electrically damped output of
a pressure transducer (Statham). A tracheotomy tube was inserted and
the animals were allowed to breathe spontaneously. The left kidney was
exposed by a flank incision, cleaned of connective tissue, and
stabilized in a Lucite cup. This kidney was bathed in 0.154 M NaCl
maintained at 37°C. After completion of surgery, rats were infused
with a solution of 0.154 M NaCl and 1% albumin at 1.5 ml/h to maintain
a euvolemic state. Micropuncture studies were begun after 60 min for stabilization.
For orthograde microperfusion of the loop of Henle (LH), a micropipette (8 µm OD) containing artificial tubular fluid (ATF) stained with FD&C green dye was inserted into a late proximal tubule. Injections of the colored ATF identified the nephron and the direction of flow. An immobile stained bone wax block was inserted into this micropuncture site via a micropipette (10-15 µm) connected to a hydraulic drive (Trent Wells, San Diego, CA) to halt tubular fluid flow. A perfusion micropipette (6-8 µm) containing ATF with test compounds or vehicle was inserted into the proximal tubule downstream from the wax block and connected to a nanoliter perfusion pump (WPI, Sarasota, FL). A pressure micropipette (1-2 µm) was inserted into the proximal tubule upstream from the wax block to measure the proximal stop-flow pressure (PSF). The pressure was recorded by a servo-null instrument (Instruments for Physiology, La Jolla, CA). Changes in PSF are an index of changes in glomerular capillary hydraulic pressure. Measurements of PSF were made in each nephron during zero loop perfusion and during perfusion with ATF at 40 nl/min, which produces a maximal TGF response, defined as the difference between PSF values recorded during perfusion of the LH with ATF at 0 and 40 nl/min.
The maximal TGF responses were determined in eight nephrons from SHR
(n = 5) and eight nephrons from WKY rats (n =5) during perfusion of the LH with ATF + vehicle and contrasted with ATF + 7-NI
(104 M). In previous studies, this was
found to be a maximally effective dose.
Ten nephrons from SHR (n = 5) and 10 from WKY rats
(n = 5) were prepared for studies of microperfusion
into the peritubular capillaries (PTC) via the efferent arteriole (EA)
of tempol (104 M) (30) dissolved in
artificial plasma (AP) (36) containing FD&C green dye. The last
proximal convolution of a nephron that was in the perfused field was
punctured, and a wax block was placed upstream. A micropipette
(8-10 µm) was inserted into the EA adjacent to the test nephron.
The LH was perfused orthogradely with ATF at zero and 40 nl/min. This
represents the maximal TGF response. Preliminary studies indicated that
a dose of tempol of 10
4 M was maximally
effective, and the response was fully reversible. Therefore, this dose
was used for these studies. After the basal measurement of TGF with LH
perfusion of ATF, the EA was perfused at 15 nl/min with AP + tempol.
After 5 min with the EA microperfusion continuing, the TGF was again
tested by perfusion of ATF at 0 and 40 nl/min into the LH. We have
shown that PTC perfusion with AP at 15-20 nl/min does not perturb
TGF responses. Only nephrons for which the surrounding interstitium was
tinted with the PTC perfusion of stained tempol solution were included
in the study.
A further group of six WKY and nine SHR were used to test the
hypothesis that the failure of TGF responses of SHR nephrons to enhance
with local microperfusion of 7-NI is due to degradation of NO by
O2 in the JGA. The maximum TGF
responses of SHR and WKY to orthograde microperfusion of ATF + vehicle
were compared with ATF + 7-NI (10
4 M)
during a 5-min microperfusion of tempol
(10
4 M) in AP at 15 nl/min into the EA.
Series 3: Dose-response relationship of TGF to microperfusion of NO
donor compound into JGA: effects of tempol. The aim of this series
was to test the hypothesis that graded doses of NO, delivered directly
into the JGA, have a reduced biologic activity in SHR nephrons that can
be corrected by a membrane-permeant SOD mimetic. Rats
were prepared as in series 2 above. The maximum TGF responses
of SHR (n = 16 nephrons) and WKY (n = 18 nephrons) to
orthograde microperfusion of ATF + SNAP
(107 M,
10
6 M,
10
5 M, and
10
4 M) were studied in the basal state,
and during EA microperfusion of tempol
(10
4 M).
Drugs. The soluble sodium salt of 7-NI was obtained from Tocris-Cookson, St. Louis, MO. Tempol was obtained from Aldrich Chemical, Milwaukee, WI. SNAP was obtained from Sigma, St. Louis, MO. These drugs were dissolved in ATF or AP. Other chemicals were obtained from Sigma.
Statistical methods. Values are reported as means ± SE. An ANOVA was applied to within-group data for SHR and WKY; where appropriate, a post hoc Dunnett's t-test was applied thereafter. Values are taken as statistically significant at P < 0.05.
Numerical data for TGF responses are presented in Tables 1-4. However, the basal TGF responses were greater in SHR than WKY. Therefore, to adjust for baseline differences, the results are shown graphically as percentage changes in TGF from baseline values, according to the criteria of Kaiser (13).
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
For series 1, immunoreactive bands corresponding to
nitrotyrosine were seen at 47, 58, 74, 89, and 102 kDa in proteins
extracted from rat renal cortex. These bands were consistently stronger in kidneys from SHR than WKY (Fig. 1).
Densitometric analysis of bands at 58 kDa confirmed that the amount of
nitrotyrosine immunoreactive protein expression was significantly
greater in SHR than WKY kidneys (Fig. 2).
|
|
Table 1 presents baseline data for rats
used in the functional studies of series 2. Compared with WKY,
SHR had similar body and kidney weights but had consistently higher
levels of MAP and slightly greater heart rates (HR). TGF parameters
showed higher values for PSF in SHR nephrons in the absence
of loop perfusion and a greater maximal TGF response, as assessed from
the difference between PSF during perfusion at 0 and 40 nl/min. The maximum response in SHR averaged 123 ± 10% of the mean
value in WKY.
|
The maximum TGF responses were contrasted in SHR and WKY nephrons
during microperfusion of 7-NI orthograde into the LH. As shown in Table
2, the maximum TGF responses again were
greater in SHR than WKY during perfusion of ATF + vehicle. The addition of 7-NI increased maximal TGF responses consistently in WKY by an
average of 30 ± 4% but had no significant effects on TGF responses of SHR (Fig. 3A).
|
|
Microperfusion of tempol into the EA blunted maximum TGF responses
significantly (P < 0.01) in both WKY and SHR nephrons (Table 3). However, as shown in Fig. 3B,
the percentage of blunting of TGF in nephrons of SHR was nearly double
that in WKY.
|
During microperfusion of tempol into the EA, orthograde loop perfusion
of 7-NI increased TGF responses in WKY rat nephrons by 28 ± 5%; this
is similar to the 30 ± 4% increase seen with 7-NI in WKY in the
absence of tempol (Table 2). However, during EA microperfusion of
tempol in SHR nephron, orthograde loop perfusion of 7-NI increased TGF
by 32 ± 5% (Fig. 3C). This is significantly (P < 0.001) more than the 5 ± 3% (not significant) change seen with 7-NI
in SHR in the absence of tempol. During tempol, the changes in maximal TGF with 7-NI become quite similar in WKY and SHR
(Fig. 3C; Table 4).
|
For series 3, log-dose response relationships for blunting of
maximal TGF responses during orthograde luminal microperfusions of SNAP
into the LH are shown in the basal state (Fig.
4A) or during EA microperfusion of
tempol (Fig. 4B). Before tempol, SNAP at
107 M was a subthreshold dose in both
WKY and SHR, as indicated by nonsignificant changes in TGF responses.
SNAP at 10
6 M blunted TGF significantly
(P < 0.05) in WKY but not in SHR nephrons. SNAP at
10
5 M blunted TGF significantly
(P < 0.05) more in WKY than in SHR nephrons. The responses to
a full dose of SNAP at 10
4 M
were similar in the two strains. As shown in Fig. 4B, in the presence of tempol microperfused into the EA,
10
7 M SNAP became an effective dose in
both SHR and WKY nephrons. Tempol enhanced the response to SNAP at each
dose, but this effect was more pronounced in SHR, whose responses
became strictly comparable to those in WKY throughout the dose range
tested. These data demonstrate that SHR have impaired sensitivity to
the NO donor compound that is corrected by local microperfusion of
tempol.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The main new findings of this study are that the kidney of the SHR has
increased immunoreactive expression of nitrotyrosine. The exaggerated
TGF responses of SHR nephrons are blunted by a membrane-permeant SOD mimetic, tempol. There is a
diminished sensitivity of TGF in SHR nephrons to local microperfusion
of the NO donor compound SNAP. Microperfusion of tempol restores a TGF
response to blockade of nNOS with 7-NI in SHR and restores a normal
dose-dependent blunting of TGF by SNAP. These data are consistent with
the hypothesis that an increase in O2
in the JGA of the SHR decreases the bioactivity of locally formed NO
and thereby increases the TGF response. NO signaling in the JGA is
restored to normal by local microperfusion of tempol.
Reports of an enhanced TGF response in SHR nephrons (9, 34, 36) are confirmed in this study. This increased TGF response was not corrected by short-term normalization of the renal perfusion pressure with a supra-aortic renal clamp (9, 36). We propose this is due to loss of buffering of TGF by JGA-derived NO, since there is loss of the normal enhancement of TGF by microperfusion of NOS inhibitors into the macula densa area of the JGA. The present studies show further that this defect is likely due to NO activity in the macula densa, since SHR failed to respond to 7-NI microperfused into the lumen of the macula densa, whereas robust and consistent responses were seen in the control WKY, as in previous studies of normal rats. 7-NI is more selective for nNOS than methyl- or nitro-arginine-based inhibitors. When infused into experimental animals, it inhibits nNOS in brain within 30 min without altering the blood pressure or the response to the endothelium-dependent agonist, ACh (4, 19, 40). Prolonged administration of 7-NI to rats enhances TGF and reduces GFR without blocking ACh-induced vasodilation of the afferent arteriole (23). Thorup and Persson (34) have shown that microperfusion of NLA into the tubular lumen near the macula densa enhances TGF responses more in WKY than SHR. Our results with 7-NI suggest that nNOS is located in the macula densa. This could be implicated in the pathogenesis of hypertension since normal rats infused with 7-NI develop hypertension that is preceded by enhancement of TGF and reduced renal function (23).
Mitchell et al. (21) have shown that tempol acts as a
membrane-permeant SOD mimetic. Tempol does not alter
hydrogen peroxide concentration in brain (28) and does not bind nor
generate NO directly (29). It is a fully validated spin-trap for
O2 (22). Tempol protects cells and
tissues against oxidative stress (20, 29). Therefore, we selected this
nitroxide to probe the functional role of
O
2 in these studies.
The cause for the apparent loss of NO function in the macula densa of SHR has been elusive. It cannot be ascribed to a general failure of SHR renal arterioles to constrict normally, since the TGF response of the SHR is overactive, and renal arteriolar vasoconstrictor responses to many agonists such as ANG II or U-46,619 are enhanced (8). Nor can it be attributed to a defect in expression of constitutive NOS isoforms in the JGA, since our recent studies have shown that the abundance of mRNA and protein for eNOS and nNOS in the JGA or renal cortex are actually enhanced in SHR, relative to WKY (36). Nor can it be due to a failure to supply the NOS substrate, L-arginine, or the NOS cofactor, tetrahydrobiopterin, to the JGA, since microperfusion of these agents into the macula densa does not modify TGF, or its response to 7-NI, in the SHR (36).
Therefore, the present studies were undertaken to assess a contrasting
hypothesis that defective NO function in the JGA of the SHR is due
rather to a failure to respond to NO, because of enhanced degradation.
It has long been known that the short biological half-life and
restricted diffusion distance of NO in blood vessel walls are due to
rapid and irreversible inactivation by oxygen radicals that oxidize NO
initially to peroxynitrite (11, 27). Peroxynitrite can nitrosylate
tyrosine epitopes leading to nitrotyrosine formation
whose expression provides an index of oxidative stress (32). A
consistent and strong band of immunoreactive nitrotyrosine was detected
in proteins extracted from the renal cortex. The nature of this
predominant nitrated tyrosine antigen is unclear. Nevertheless, its
expression was enhanced consistently in the renal cortex of SHR,
compared with WKY. This finding extends our previous observation that
isoprostane excretion is increased in SHR and that this increase can be
normalized by a 2-wk administration of tempol (30). Isoprostanes are
formed by nonenzymic interactions between
O2 and arachidonate. These findings at
the level of the kidney and whole circulation complement extensive previous studies of isolated vessels of SHR that have shown an enhanced
agonist-induced release of EDCF that accounts for a diminished EDRF
activity (3). EDCF depends upon oxygen radicals (1), cyclooxygenase
(17), and thromboxane-PGH2 (TP) receptors
(2). In a recent study, Brannstrom et al. (6) have shown that much of
the exaggerated TGF response in SHR is dependent on activation of TP
receptors. This may relate to increased
O
2 activity, through formation of
isoprostanes that act on TP receptors (26). An interaction of
O
2 with both NO and arachidonate could
represent an additional level of regulation of TGF during oxidant stress.
Previous studies of EDCF and O2 have
shown that they are important mediators of large vessel responses in hypertension and atherosclerosis (1). The present studies are the first
to demonstrate a role for O
2 in the JGA in regulation of afferent arteriolar tone via interaction with NO.
Evidence that oxidant stress and O2
account for exaggerated preglomerular vasoconstriction, enhanced TGF, and a diminished functional role for NO in the JGA of the SHR were
derived from two sets of experiments.
First, the blunting of TGF by the NO donor compound, SNAP, showed a
diminished sensitivity but a preserved maximal responsiveness. The
preserved responsiveness suggests that NO responsive elements in the
SHR afferent arteriole were intact. The diminished
sensitivity to SNAP in SHR is consistent with enhanced NO degradation
via O2. This conclusion was
strengthened by the observation that microperfusion of tempol via the
EA normalized the sensitivity to SNAP in the SHR. Our interpretation is
that the SOD mimetic, tempol, metabolizes
O
2 to H2O2 and
O2, which do not directly interact with NO. Therefore,
tempol enhances the effectiveness of physiologically relevant
concentrations of NO by diminishing its rapid degradation. Since this
effect of tempol is more pronounced in SHR than WKY, it implies that O
2-induced NO degradation similarly is
more pronounced in SHR than WKY nephrons.
Second, we observed that nephrons of SHR were approximately twice as
responsive as WKY to microperfusion of tempol, as shown by twice as
great a fractional blunting of TGF in the hypertensive model (Fig.
3B). If this effect of tempol is due to activation of a latent
NO-dependent vasodilator mechanism that offsets TGF responses, we
argued that tempol should restore a normal response to nNOS inhibition
in the SHR. Indeed, microperfusion of tempol into the EA normalized the
response to microperfusion of 7-NI into the macula densa of the SHR
(Fig. 3C). We conclude that the failure of the JGA
L-arginine-NO pathway to function in the SHR can be
ascribed to excessive NO degradation by
O2, rather than to an intrinsic
failure in the system to generate NO in the macula densa or to respond
to NO in the vessel wall.
The present studies leave unanswered the source of
O2 generated in the JGA. Nitrotyrosine
immunoreactivity in the 2-kidney, 1-clipped Goldblatt hypertensive rat
model is expressed densely in the interstitium and the
extraglomerular mesangial cells between the macula densa and the
afferent arteriole (5). The interstitium and extraglomerular mesangium
may form a barrier that isolates NO generated in the macula densa from targets in the afferent arteriole. NADPH oxidase is the predominant source of O
2 generation in the vessel
wall of hypertensive models (25). It is expressed strongly in
adventitial fibroblasts (24) and mesangial cells (12). Mesangial cell NADPH oxidase is stimulated to generate
O
2 by ANG II acting on AT1
receptors (12). Therefore, NADPH oxidase could be the predominant
source of O
2 generation in the JGA.
Since this source of O2 is strongly
dependent on AT1 receptor activity, the level of oxidative
stress in the SHR may vary with age. We have tested 9- to 10-wk-old
rats. This is a time when hypertension is fully achieved and an
exaggerated TGF is present. Although enhanced TGF is more often seen in
young SHR (6, 9, 11), decreased renal blood flow and GFR have been
observed in mature SHR (10, 14, 34). The level of ANG II also varies in
the SHR. Most studies agree, however, that blockade of ANG II with
either angiotensin converting enzyme inhibitors or AT1
receptor antagonists reduces MAP in the SHR, regardless of age
(reviewed in Ref. 16). Therefore, the effectiveness of NO in regulating
TGF may well depend on the physiological state of the animal, which
includes the level of oxidative stress and ANG II activity.
Previous studies have shown the importance of
O2 in signaling ANG II actions in
blood vessel wall (25). ANG II concentrations probably are higher in
the JGA than anywhere else in the body. The exaggerated TGF response of
the SHR kidney is dependent on AT1 receptors (6).
Therefore, the JGA of the SHR should be a prominent site for ANG
II-induced O
2 generation. An
overactive TGF mechanism would contribute to inappropriate preglomerular renal vasoconstriction and a limited capacity to excrete
a salt load rapidly and effectively. As such, it may be an important
pro-hypertensive mechanism. Indeed, Ollerstam et al. (23)
have shown that inhibition of nNOS with 7-NI first increases TGF
responsiveness and reduces renal function of normal rats. Later, 7-NI
increases the blood pressure. The present studies have
shown that one factor responsible for an exaggerated TGF response in
SHR is overproduction of O
2 leading to
a functional state of NO deficiency. That this could contribute to
maintenance of hypertension is shown by the normalization of renal
vasoconstriction and hypertension by short-term infusion of tempol (31)
and by the selective reduction in blood pressure in the SHR by 2 wk of
oral tempol administration (30).
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Delphine Nguyen for preparing the manuscript.
![]() |
FOOTNOTES |
---|
This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants DK-36079 and DK-49870 and by funds from the George E. Schreiner Chair of Nephrology.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: W. J. Welch, Georgetown Univ. Medical Center, Bldg. D, Rm. 395, 4000 Reservoir Road, NW, Washington, DC 20007 (E-mail: welchw{at}gusun.georgetown.edu).
Received 10 May 1999; accepted in final form 9 December 1999.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Auch-Schwelk, W,
Katusic ZS,
and
Vanhoutte PM.
Contractions to oxygen-derived free radicals are augmented in aorta of the spontaneously hypertensive rat.
Hypertension
13:
859-864,
1989[Abstract].
2.
Auch-Schwelk, W,
Katusic ZS,
and
Vanhoutte PM.
Thromboxane A2 receptor antagonists inhibit endothelium-dependent contractions.
Hypertension
15:
699-703,
1990[Abstract].
3.
Auch-Schwelk, W,
Katusic ZS,
and
Vanhoutte PM.
Nitric oxide inactivates endothelium-derived contracting factor in the rat aorta.
Hypertension
19:
442-445,
1992[Abstract].
4.
Babbedge, RC,
Bland-Ward PA,
Hart SL,
and
Moore PK.
Inhibition of rat cerebellar nitric oxide synthase by 7-nitroindazole and related substituted indazoles.
Br J Pharmacol
110:
225-228,
1993[Abstract].
5.
Bosse, HM,
and
Bachmann S.
Immunohistochemically detected protein nitration indicates sites of renal nitric oxide release in Goldblatt hypertension.
Hypertension
30:
948-952,
1997
6.
Brannstrom, K,
Morsing P,
and
Arendshorst WJ.
Exaggerated tubuloglomerular feedback activity in genetic hypertension is mediated by ANG II and AT1 receptors.
Am J Physiol Renal Fluid Electrolyte Physiol
270:
F749-F755,
1996
7.
Briggs, JP,
and
Schnermann J.
Control of renin release and glomerular vascular tone by the juxtaglomerular apparatus.
In: Hypertension: Pathophysiology, Diagnosis and Management, edited by Laragh JH,
and Brenner BM.. New York: Raven, 1995, p. 1359-1384.
8.
Chatziantoniou, C,
Daniels FH,
and
Arendshorst WJ.
Exaggerated renal vascular reactivity to angiotensin and thromboxane in young genetically hypertensive rats.
Am J Physiol Renal Fluid Electrolyte Physiol
259:
F372-F382,
1990
9.
Dilley, JR,
and
Arendshorst WJ.
Enhanced tubuloglomerular feedback activity in rats developing spontaneous hypertension.
Am J Physiol Renal Fluid Electrolyte Physiol
247:
F672-F679,
1984[ISI][Medline].
10.
Granstrom, SO,
Granstrom E,
Fellstrom B,
and
Lind L.
Regional hemodynamic differences between normotensive and spontaneously hypertensive rats: a microsphere study.
Physiol Res
47:
9-15,
1998[ISI][Medline].
11.
Gryglewski, RJ,
Palmer RMJ,
and
Moncada S.
Superoxide anion is involved in breakdown of endothelium-derived vascular relaxing factor.
Nature
320:
454-456,
1986[ISI][Medline].
12.
Jaimes, EA,
Galceran JM,
and
Raij L.
Angiotensin II induces superoxide anion production by mesangial cells.
Kidney Int
54:
775-784,
1998[ISI][Medline].
13.
Kaiser, L.
Adjusting for baseline: change or percentage change?
Stat Med
8:
1183-1190,
1989[ISI][Medline].
14.
Kawabata, M,
Ogawa T,
and
Takabatake T.
Effects of lemildipine, a new calcium channel blocker on renal microcirculation in SHR.
Hypertens Res
21:
121-126,
1998[Medline].
15.
Kone, BC,
and
Baylis C.
Biosynthesis and homeostatic roles of nitric oxide in the normal kidney.
Am J Physiol Renal Physiol
272:
F561-F578,
1997
16.
Levens, NR,
de Gasparo M,
Wood JM,
and
Bottari SP.
Could the pharmacological differences observed between angiotensin II antagonists and inhibitors of angiotensin converting enzyme be clinical beneficial?
Pharmacol Toxicol
71:
241-249,
1992[ISI][Medline].
17.
Lin, L,
and
Nasjletti A.
Role of endothelium-derived prostaglandin in angiotensin-induced vasoconstriction.
Hypertension
18:
158-164,
1991[Abstract].
18.
Luscher, TF,
and
Vanhoutte PM.
Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat.
Hypertension
8:
344-348,
1986[Abstract].
19.
MacKenzie, GM,
Rose S,
Bland-Ward PA,
Moore PK,
Jenner P,
and
Marsden CD.
Time course of inhibition of brain nitric oxide synthase by 7-nitroindazole.
Neuroreport
5:
1993-1996,
1994[ISI][Medline].
20.
Mitchell, JB,
De Graff W,
Kaufman D,
Krishna MC,
Samuni A,
Finkelstein E,
Ahn MS,
Hahn SM,
Gamson J,
and
Russo A.
Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimetic, tempol.
Arch Biochem Biophys
289:
62-70,
1991[ISI][Medline].
21.
Mitchell, JB,
Samuni A,
Krishna MC,
De Graff WG,
Ahn MS,
Samuni U,
and
Russo A.
Biologically active metal-independent superoxide dismutase mimetics.
Biochemistry
29:
2802-2807,
1990[ISI][Medline].
22.
Nilsson, UA,
Olsson LI,
Carlin G,
and
Bylund-Fellenius AC.
Inhibition of lipid peroxidation by spin labels: relationships between structure and function.
J Biol Chem
264:
11131-11135,
1989
23.
Ollerstam, A,
Pittner J,
Persson AEG,
and
Thorup C.
Increased blood pressure in rats after long-term inhibition of the neuronal isoform of nitric oxide synthase.
J Clin Invest
99:
2212-2218,
1997
24.
Pagano, PJ,
Chanock SJ,
Siwik DA,
Colucci WS,
and
Clark JK.
Angiotensin II induces p67phox mRNA expression and NADPH oxidase superoxide generation in rabbit aortic adventitial fibroblasts.
Hypertension
32:
331-337,
1998
25.
Pagano, PJ,
Clark JK,
Cifuentes-Pagano ME,
Clark SM,
Callis GM,
and
Quinn MT.
Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II.
Proc Natl Acad Sci USA
94:
14483-14488,
1997
26.
Roberts, ILJ,
and
Morrow JD.
The generation and actions of isoprostanes (Abstract).
Biochim Biophys Acta
1345:
135,
1997.
27.
Rubanyi, GM,
and
Vanhoutte PM.
Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor.
Am J Physiol Heart Circ Physiol
250:
H822-H827,
1986
28.
Samuni, A,
Krishna CM,
Mitchell JB,
Collins CR,
and
Russo A.
Superoxide reaction with nitroxides.
Free Radic Res Commun
9:
241-249,
1990[ISI][Medline].
29.
Samuni, A,
Winkelsberg A,
Pinson A,
Hahn SM,
Mitchell JB,
and
Russo A.
Nitroxide stable radicals protect beating cardiomyocytes against oxidative damage.
J Clin Invest
87:
1526-1530,
1991[ISI][Medline].
30.
Schnackenberg, C,
and
Wilcox CS.
Two-week administration of tempol attenuates both hypertension and renal excretion of 8-iso prostaglandin F2a.
Hypertension
33:
424-428,
1999
31.
Schnackenberg, CG,
Welch WJ,
and
Wilcox CS.
Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide.
Hypertension
32:
59-64,
1998
32.
Stamler, JS,
and
Hausladen A.
Oxidative modifications in nitrosative stress.
Nat Struct Biol
5:
247-249,
1998[ISI][Medline].
33.
Terada, Y,
Tomita K,
Nonoguchi H,
and
Marumo F.
Polymerase chain reaction localization of constitutive nitric oxide synthase and soluble guanylate cyclase messenger RNAs in microdissected rat nephron segments.
J Clin Invest
90:
659-665,
1992[ISI][Medline].
34.
Thorup, C,
and
Persson AEG
Impaired effect of nitric oxide synthesis inhibition on tubuloglomerular feedback in hypertensive rats.
Am J Physiol Renal Fluid Electrolyte Physiol
271:
F246-F252,
1996
35.
Tojo, A,
Madsen KM,
and
Wilcox CS.
Expression of immunoreactive nitric oxide synthase isoforms in rat kidney: effects of dietary salt and losartan.
Jpn Heart J
36:
389-398,
1995[ISI][Medline].
36.
Welch, WJ,
Tojo A,
Lee J-U,
Kang DG,
Schnackenberg CG,
and
Wilcox CS.
Nitric oxide synthase in the JGA of the SHR: expression and role in tubuloglomerular feedback.
Am J Physiol Renal Physiol
277:
F130-F138,
1999
37.
Wilcox, CS,
Deng X,
and
Welch WJ.
NO generation and action during changes in salt intake: Roles of nNOS and macula densa.
Am J Physiol Regulatory Integrative Comp Physiol
274:
R1588-R1593,
1998
38.
Wilcox, CS,
and
Welch WJ.
TGF and nitric oxide: effects of salt intake and salt-sensitive hypertension.
Kidney Int
49:
S9-S13,
1996.
39.
Wilcox, CS,
Welch WJ,
Murad F,
Gross SS,
Taylor G,
Levi R,
and
Schmidt HH.
Nitric oxide synthase in macula densa regulates glomerular capillary pressure.
Proc Natl Acad Sci USA
89:
11993-11997,
1992[Abstract].
40.
Wolff, DJ,
and
Gribin BJ.
The inhibition of the constitutive and inducible nitric oxide synthase isoforms by indazole agents.
Arch Biochem Biophys
311:
300-306,
1994[ISI][Medline].